PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

NCT04601467 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

243

Enrollment

OTHER

Sponsor class

Stopped The study was terminated early on 14th September 2023 by the main funding company because of financial futility. We were able to enroll 243 of the initial planned 360 participants and randomised 209 participants of the intial planned 286.

Conditions

Acute Coronary Syndrome

Interventions

DRUG: AZD5718
DRUG: Placebo

Sponsor

National University Heart Centre, Singapore

Collaborators

[object Object]
[object Object]